Many patients do not fully recover after infection. Post-COVID, Post-sepsis, Post-Lyme or Post-EBV are increasingly recognized, but the symptoms often remain "invisible": fatigue, muscle and joint pain, brain fog, decreased resistance. Standard blood values or imaging do not always explain this.

Multi-omics makes this hidden layer visible: it exposes how DNA, microbiome and metabolites together determine immune response and recovery.

The clinical problem

• Classic diagnostics often show normal values while the patient maintains disabling symptoms.
• Post-infectious syndromes are still too often seen as "residual symptoms" or "psychological," causing frustration for both physician and patient.
• Recent multi-omics studies show that post-infection is associated with persistent immune activation, mitochondrial dysfunction and microbiome disturbances.

What recent multi-omics studies show

1. Compartmentalized immune responses
   - Rostomily et al., bioRxiv 2025: showed that in Lyme, the immune response proceeds differently by tissue/compartment, explaining why classical markers often fail.
2. Mitochondrial dysfunction
   - Ward & Schlichtholz, IJMS 2024: Post-COVID is characterized by mitochondrial abnormalities that undermine energy efficiency and recovery.
3. Multisystem inflammatory syndromes
   - Dourdouna et al., Children 2024: Persistent abnormalities in immune pathways were found in MIS-C after COVID via proteomics, similar to adult post-infectious images.
4. AI-driven multi-omics models
   - Xiong et al., Nature Medicine 2025: integrated multi-omics and clinical symptoms for ME/CFS, and found distinct subtypes of patients with metabolic and immunological abnormalities.
5. Persistent inflammation & metabolic remodeling
   - Acierno et al., PMC 2025: described how chronic infections induce metabolic remodeling and contribute to a "post-infectious metabolic syndrome."

Innovative solutions for the clinic

1. Immune Resilience Index
   - A score that reveals the crosstalk between immune system, microbiome and metabolites.
2. Mitochondrial monitoring
   - Metabolites quantifying energy efficiency (ATP, lactate, amino acid pathways) → objective markers of fatigue.
3. Inflammation profiles
   - Multi-omics detects subtle chronic activation (e.g. IL-6, TNFα pathways), even when standard values are normal.
4. Crosstalk axes visualize
   - Gut-lung axis in post-pneumonia, gut-heart axis in post-myocarditis, gut-brain axis in brain fog after EBV or COVID.

Why My InnerSelfie is unique

• Multi-omics integration: DNA, microbiome and metabolites in one profile.
• Crosstalk focus: visualizing the dialogue between organs, immune system and gut.
• Preventive precision: risks of long-term complaints are detected early.
• Additional tool for the physician: our data enrich clinical decision-making; decisions always remain in the hands of the physician.
• Tomorrow's care: innovative, preventive and always customized. Innovation of today becomes the standard of tomorrow - substantiated, safe, risk-free.

Key insights

• Post-infectious symptoms are biologically explainable through multi-omics.
• Studies show mitochondrial dysfunction, immune activation and dysbiosis in post-COVID, Lyme and ME/CFS.
• My InnerSelfie offers doctors an objective tool to detect and monitor these hidden processes.

Scientific references

• Rostomily C, Bhalla A, Hampton H, et al. Multiomics reveals compartmentalized immune responses in Lyme disease. bioRxiv. 2025.
• Ward C, Schlichtholz B. Post-acute sequelae and mitochondrial aberration in SARS-CoV-2 infection. IJMS. 2024.
• Dourdouna MM, Tatsi EB, Syriopoulou V, et al. Proteomic signatures of MIS-C after COVID-19. Children. 2024.
• Xiong R, Aiken E, Caldwell R, et al. AI-driven multi-omics modeling of ME/CFS. Nature Medicine. 2025.
• Acierno C, Nevola R, Barletta F, et al. Multidrug-resistant infections and metabolic syndrome: a post-infectious model. PMC. 2025.
• Patrascu R, Dumitru CS. Persistent sequelae in COVID-19 patients revealed by multi-omics profiling. J Clin Med. 2025.